A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib

被引：1

作者：

Chen, Kaiyan ^{[1
,2
,3
]}

Zhang, Fanrong ^{[1
,4
]}

Pan, Guoqiang ^{[1
,2
,3
,5
]}

Sheng, Jiamin ^{[1
,2
,3
,5
]}

Ye, Junyi ^{[6
]}

Xu, Yanjun ^{[1
,2
,3
]}

Yu, Xiaoqing ^{[1
,2
,3
]}

Huang, Zhiyu ^{[1
,2
,3
]}

Fan, Yun ^{[1
,2
,3
]}

机构：

[1] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China

[2] Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China

[3] Zhejiang Canc Hosp, Dept Thorac Med Oncol, Hangzhou, Peoples R China

[4] Zhejiang Canc Hosp, Dept Breast Surg, Hangzhou, Peoples R China

[5] Wenzhou Med Univ, Clin Med Coll 1, Dept Oncol, Wenzhou, Peoples R China

[6] Bioinformat Dept, Burning Rock Biotech, Guangzhou, Peoples R China

来源：

关键词：

Crizotinib; MET; Non-small-cell lung cancer; RET; Resistance; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; OPEN-LABEL; CARCINOMAS; PHASE-2;

D O I：

10.1016/j.cllc.2020.07.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：E1 / E4

页数：4

共 32 条